MENU
+Compare
RICFY
Stock ticker: OTC
AS OF
Sep 23 closing price
Price
$14.99
Change
-$0.48 (-3.10%)
Capitalization
12.65B

RICFY stock forecast, quote, news & analysis

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals... Show more

RICFY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for RICFY with price predictions
Sep 24, 2025

RICFY's RSI Indicator is remaining in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for RICFY crossed bullishly above the 50-day moving average on September 08, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RICFY advanced for three days, in of 26 cases, the price rose further within the following month. The odds of a continued upward trend are .

RICFY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 75 cases where RICFY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RICFY as a result. In of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RICFY turned negative on September 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 19 similar instances when the indicator turned negative. In of the 19 cases the stock turned lower in the days that followed. This puts the odds of success at .

RICFY moved below its 50-day moving average on September 23, 2025 date and that indicates a change from an upward trend to a downward trend.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.559) is normal, around the industry mean (9.460). P/E Ratio (26.074) is within average values for comparable stocks, (23.480). Projected Growth (PEG Ratio) (1.092) is also within normal values, averaging (1.788). Dividend Yield (0.023) settles around the average of (0.028) among similar stocks. P/S Ratio (4.283) is also within normal values, averaging (3.429).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RICFY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RICFY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

A.I.Advisor
published Dividends

RICFY paid dividends on June 05, 2025

Recordati Industria Chimica e Farmaceutica S.p.A. RICFY Stock Dividends
А dividend of $0.19 per share was paid with a record date of June 05, 2025, and an ex-dividend date of May 20, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 89.06B. The market cap for tickers in the group ranges from 72.83K to 640.6B. LLY holds the highest valuation in this group at 640.6B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -1%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 12%. OTSKF experienced the highest price growth at 29%, while CSPCY experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -9%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was 15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 69
Price Growth Rating: 55
SMR Rating: 60
Profit Risk Rating: 79
Seasonality Score: -33 (-100 ... +100)
View a ticker or compare two or three
RICFY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Via Matteo Civitali 1
Phone
+39 2487871
Employees
4369
Web
https://www.recordati.com